A thiazole-based hydrazone derivative, (E)-4-(4-chlorophenyl)-2-(2-(2,3-dihydro-1H-inden-1-ylidene)hydrazinyl)thiazole (CPIHT), was synthesized via a one-pot multicomponent reaction. The structure of the synthesized compound was confirmed using FT-IR, ¹H NMR, and ¹³C NMR spectroscopic techniques. The pharmacokinetic properties of CPIHT were evaluated using the SwissADME web tool. The results indicated favourable physicochemical parameters, including a topological polar surface area (TPSA) of 65.52 Ų, a consensus Log Po/w value of 4.71, and moderate water solubility (Log S = –5.74). The compound exhibited high gastrointestinal absorption and predicted blood–brain barrier permeability, while it was not identified as a substrate for P-glycoprotein. Furthermore, CPIHT satisfied major drug-likeness criteria, including Lipinski, Ghose, Veber, and Egan rules. The bioavailability radar and BOILED-Egg models further supported the favourable pharmacokinetic and oral bioavailability profile of the compound. Molecular docking studies were performed against Mycobacterium tuberculosis enoyl-acyl carrier protein reductase (InhA) (PDB ID: 4TZK), a key enzyme involved in the biosynthesis of mycolic acids essential for the mycobacterial cell wall. The docking results revealed that CPIHT binds strongly within the active site of the enzyme with a binding affinity of –9.5 kcal/mol. The ligand forms a stable ligand–protein complex through several non-covalent interactions, including a π–sulphur interaction with MET199 and a π–π T-shaped interaction with TYR158. In addition, multiple hydrophobic contacts such as alkyl and π–alkyl interactions with residues PHE149 and LEU207 further stabilize the complex. These interactions contribute to the effective stabilization of the ligand within the enzyme binding pocket, indicating favourable binding affinity. Overall, the combined ADME and molecular docking results suggest that CPIHT possesses promising drug-like characteristics and may serve as a potential lead compound for the development of new antitubercular agents.